Rebel News team, led by Rebel Commander Ezra Levant and Australia Bureau Chief Avi Yemini, managed to catch Pfizer CEO Albert Bourla on the streets of Davos (WEF 2023), where they asked the questions people around the world want answered.

Nearly 30 important questions were asked by Ezra Levant and Avi Yemini, but the Pfizer head had no answers for the public.

In March 2020, the World Health Organization declared COVID-19 a global pandemic. By December, vaccines were being made available to the public. Since that time, and for a variety of reasons, millions of people across the world have raised questions about these vaccines.

The mainstream media often neglects these concerns as conspiracies, refusing to ask executives of pharmaceutical companies, which purchase ad space on mainstream news programming, these difficult questions.

That's why the Rebel News team is in Davos, Switzerland, this week covering the World Economic Forum's annual summit — so we can ask the tough questions others either can't or won't.
SOURCE: https://www.rebelnews.com/every_question_we_asked_pfizer_ceo_albert_bourla 

(credit: Rebel News)𝘈𝘭𝘭 𝘤𝘳𝘦𝘥𝘪𝘵 𝘨𝘰𝘦𝘴 𝘵𝘰 𝘤𝘰𝘱𝘺𝘳𝘪𝘨𝘩𝘵 𝘩𝘰𝘭𝘥𝘦𝘳(𝘴).* 
Please visit and support www.rebelnews.com if you appreciate this content.

NOTE: 𝘛𝘩𝘦 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯, 𝘪𝘥𝘦𝘢𝘴, 𝘢𝘯𝘥 𝘷𝘪𝘦𝘸𝘴 𝘪𝘯 𝘵𝘩𝘪𝘴 𝘤𝘰𝘯𝘵𝘦𝘯𝘵 𝘢𝘳𝘦 𝘵𝘩𝘰𝘴𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘢𝘶𝘵𝘩𝘰𝘳(𝘴) / 𝘴𝘱𝘦𝘢𝘬𝘦𝘳(𝘴) / 𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘦𝘳(𝘴) 𝘢𝘯𝘥 𝘮𝘢𝘺 𝘯𝘰𝘵 𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵 𝘮𝘺 𝘰𝘸𝘯 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭 𝘣𝘦𝘭𝘪𝘦𝘧𝘴/𝘷𝘪𝘦𝘸𝘴; 𝘐 𝘥𝘰 𝘯𝘰𝘵 𝘤𝘭𝘢𝘪𝘮 𝘵𝘰 𝘢𝘨𝘳𝘦𝘦 𝘰𝘳 𝘥𝘪𝘴𝘢𝘨𝘳𝘦𝘦 𝘸𝘪𝘵𝘩 𝘢𝘯𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘤𝘰𝘯𝘵𝘦𝘯𝘵𝘴 𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘦𝘥. 𝘛𝘩𝘪𝘴 𝘤𝘰𝘯𝘵𝘦𝘯𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘪𝘯𝘵𝘦𝘯𝘥𝘦𝘥 𝘢𝘴 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘰𝘳 𝘭𝘦𝘨𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦.𝘔𝘺 𝘱𝘳𝘪𝘮𝘢𝘳𝘺 𝘨𝘰𝘢𝘭 𝘪𝘴 𝘵𝘰 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘢𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘴𝘰 𝘰𝘵𝘩𝘦𝘳𝘴 𝘮𝘢𝘺 𝘤𝘰𝘮𝘦 𝘵𝘰 𝘵𝘩𝘦𝘪𝘳 𝘰𝘸𝘯, 𝘮𝘰𝘳𝘦 𝘥𝘪𝘷𝘦𝘳𝘴𝘦𝘭𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘦𝘥, 𝘤𝘰𝘯𝘤𝘭𝘶𝘴𝘪𝘰𝘯𝘴.

𝘍𝘈𝘐𝘙-𝘜𝘚𝘌 𝘊𝘖𝘗𝘠𝘙𝘐𝘎𝘏𝘛 𝘋𝘐𝘚𝘊𝘓𝘈𝘐𝘔𝘌𝘙
*𝘊𝘰𝘱𝘺𝘳𝘪𝘨𝘩𝘵 𝘋𝘪𝘴𝘤𝘭𝘢𝘪𝘮𝘦𝘳 𝘜𝘯𝘥𝘦𝘳 𝘚𝘦𝘤𝘵𝘪𝘰𝘯 107 𝘰𝘧 𝘵𝘩𝘦 𝘊𝘰𝘱𝘺𝘳𝘪𝘨𝘩𝘵 𝘈𝘤𝘵 1976, 𝘢𝘭𝘭𝘰𝘸𝘢𝘯𝘤𝘦 𝘪𝘴 𝘮𝘢𝘥𝘦 𝘧𝘰𝘳 "𝘧𝘢𝘪𝘳 𝘶𝘴𝘦" 𝘧𝘰𝘳 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘤𝘳𝘪𝘵𝘪𝘤𝘪𝘴𝘮, 𝘤𝘰𝘮𝘮𝘦𝘯𝘵𝘪𝘯𝘨, 𝘯𝘦𝘸𝘴 𝘳𝘦𝘱𝘰𝘳𝘵𝘪𝘯𝘨, 𝘵𝘦𝘢𝘤𝘩𝘪𝘯𝘨, 𝘴𝘤𝘩𝘰𝘭𝘢𝘳𝘴𝘩𝘪𝘱, 𝘢𝘯𝘥 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩. 𝘍𝘢𝘪𝘳 𝘶𝘴𝘦 𝘪𝘴 𝘢 𝘶𝘴𝘦 𝘱𝘦𝘳𝘮𝘪𝘵𝘵𝘦𝘥 𝘣𝘺 𝘤𝘰𝘱𝘺𝘳𝘪𝘨𝘩𝘵 𝘴𝘵𝘢𝘵𝘶𝘵𝘦 𝘵𝘩𝘢𝘵 𝘮𝘪𝘨𝘩𝘵 𝘰𝘵𝘩𝘦𝘳𝘸𝘪𝘴𝘦 𝘣𝘦 𝘪𝘯𝘧𝘳𝘪𝘯𝘨𝘪𝘯𝘨. 𝘕𝘰𝘯-𝘱𝘳𝘰𝘧𝘪𝘵, 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘰𝘳 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘵𝘪𝘱𝘴 𝘵𝘩𝘦 𝘣𝘢𝘭𝘢𝘯𝘤𝘦 𝘪𝘯 𝘧𝘢𝘷𝘰𝘳 𝘰𝘧 𝘧𝘢𝘪𝘳 𝘶𝘴𝘦.